1. Ukuxilongwa kanye nokwelashwa kokuqala komdlavuza wamaphaphu
U-Lu ogulayo watholakala ene-lung adenocarcinoma kanye ne-lymph node metastasis ngo-August 26, 2005. I-lobectomy ephansi kwesokunxele yenziwa ngo-September 22, 2005. I-Carboplatin ehlangene ne-taxotere yasetshenziswa izikhathi ezingu-4 ngemva kokuhlinzwa. Ngomhla zi-3 ku-Agasti 2007, ngenxa ye-pleural effusion, ukuxilongwa kwaqinisekiswa ukuthi kuphindaphinda, futhi welashwa nge-Tarceva (inani lemijikelezo ayaziwa). Ngomhla ziyisi-8 kuJanuwari, i-2008, inqubekelaphambili yomdlavuza yatholakala ekuhlolweni kabusha, futhi ukwelashwa kwe-Tarceva kwamiswa futhi ukwelashwa kwe-Libita kwaqalwa imijikelezo engu-16. Ngesikhathi esifanayo, i-metastasis ye-vertebral hip yatholakala futhi imijikelezo ye-4 ye-Zetai yenziwa.
2. Isikhathi sokuqala sokubamba iqhaza ezivivinyweni zomtholampilo, isimo siyalawuleka.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the isisu was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. Ocwaningweni lwesibili lomtholampilo, isimila sanyamalala ngokusobala.
On August 6, 2012, Mr. Lu participated in the AP26113 drug isivivinyo somtholampilo at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the isimila ebuchosheni decreased and became large.
4. Zitholele ukuguqulwa kwezakhi zofuzo ezingavamile futhi ubheke phambili ekubambeni iqhaza ezivivinyweni ezintsha zomtholampilo
Ukuhlolwa kabusha ngoJulayi 2014, i-PET yomzimba wonke yabonisa: Izilonda zobuchopho zazizinzile, futhi isifuba sasinenqubekelaphambili esobala. Ngomhla ziyi-12 kuNhlaba wezi-2014, imigqa yeseli esolwayo ye-anti-AP26113 (amaseli ama-3, amakhulu kunawo wonke angu-1.1 cm) yenziwa e-Massachusetts General Hospital futhi yaqhubeka nokuthatha i-AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s i-neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
